Details for New Drug Application (NDA): 216917
✉ Email this page to a colleague
NDA 216917 describes TOLTERODINE TARTRATE, which is a drug marketed by Ajanta Pharma Ltd, Aurobindo Pharma Usa, Hetero Labs Ltd Iii, Inventia Hlthcare, Teva Pharms Usa, Torrent, Unichem, Utopic Pharms, Apotex Corp, Elysium, Hetero Labs Ltd V, Ivax Sub Teva Pharms, Macleods Pharms Ltd, Norvium Bioscience, and Unique, and is included in sixteen NDAs. It is available from sixteen suppliers. Additional details are available on the TOLTERODINE TARTRATE profile page.
The generic ingredient in TOLTERODINE TARTRATE is tolterodine tartrate. There are twenty-three drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the tolterodine tartrate profile page.
The generic ingredient in TOLTERODINE TARTRATE is tolterodine tartrate. There are twenty-three drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the tolterodine tartrate profile page.
Summary for 216917
| Tradename: | TOLTERODINE TARTRATE |
| Applicant: | Unichem |
| Ingredient: | tolterodine tartrate |
| Patents: | 0 |
Pharmacology for NDA: 216917
| Mechanism of Action | Cholinergic Muscarinic Antagonists |
Medical Subject Heading (MeSH) Categories for 216917
Suppliers and Packaging for NDA: 216917
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| TOLTERODINE TARTRATE | tolterodine tartrate | CAPSULE, EXTENDED RELEASE;ORAL | 216917 | ANDA | Unichem Pharmaceuticals (USA), Inc. | 29300-306 | 29300-306-05 | 500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (29300-306-05) |
| TOLTERODINE TARTRATE | tolterodine tartrate | CAPSULE, EXTENDED RELEASE;ORAL | 216917 | ANDA | Unichem Pharmaceuticals (USA), Inc. | 29300-306 | 29300-306-13 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (29300-306-13) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 2MG | ||||
| Approval Date: | Aug 27, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 4MG | ||||
| Approval Date: | Aug 27, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
